Wim Wynendaele
- Molecular Biology
- Oncology top 10%
- Cancer Research top 10%
- Pulmonary and Respiratory Medicine
- Immunology and Allergy top 5%
- Co-authors
- A.T. van OosteromRobert ParidaensHans WildiersRonald HoekstraFerry A.L.M. EskensJoachim DrevsHerlinde DumezJaap Verweij
- Topics
- Cancer Treatment and Pharmacology (8 papers)HER2/EGFR in Cancer Research (5 papers)Angiogenesis and VEGF in Cancer (5 papers)
- Partner nations
- BelgiumNetherlandsFrance
In The Last Decade
Wim Wynendaele
25 papers receiving 674 citations
Peers
Comparison fields: 5 of 79
- Molecular Biology 303
- Oncology 303
- Cancer Research 182
- Pulmonary and Respiratory Medicine 138
- Immunology and Allergy 104
Countries citing papers authored by Wim Wynendaele
This map shows the geographic impact of Wim Wynendaele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim Wynendaele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim Wynendaele more than expected).
Fields of papers citing papers by Wim Wynendaele
This network shows the impact of papers produced by Wim Wynendaele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim Wynendaele. The network helps show where Wim Wynendaele may publish in the future.
Co-authorship network of co-authors of Wim Wynendaele
This figure shows the co-authorship network connecting the top 25 collaborators of Wim Wynendaele. A scholar is included among the top collaborators of Wim Wynendaele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim Wynendaele. Wim Wynendaele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 5 | |
| 4 | 22 | |
| 5 | 133 | |
| 6 | 39 | |
| 7 | 19 | |
| 8 | 2 | |
| 9 | 1 | |
| 10 | 6 | |
| 11 | 178 | |
| 12 | 73 | |
| 13 | PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. | 12 |
| 14 | 1 | |
| 15 | 60 | |
| 16 | 91 | |
| 17 | Neoadjuvant chemotherapy with sequential doxorubicine (DOX) and docetaxel (DOC) in locally advanced breast cancer (LABC): a pilot study | 5 |
| 18 | Neoadjuvant/primary chemotherapy in cancer treatment: what advantage? | 1 |
| 19 | Vascular endothelial growth factor (VEGF): Plasma is the place to be | 2 |
| 20 | 3 |
About Wim Wynendaele
Wim Wynendaele is a scholar working on Oncology, Internal Medicine and Cancer Research, having authored 25 papers that have together received 696 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), HER2/EGFR in Cancer Research (5 papers) and Angiogenesis and VEGF in Cancer (5 papers). The work is most often cited by research in Immunology and Allergy (104 citations), Cancer Research (182 citations) and Oncology (303 citations). Wim Wynendaele has collaborated with scholars based in Belgium, Netherlands and France. Frequent co-authors include A.T. van Oosterom, Robert Paridaens, Hans Wildiers, Ronald Hoekstra, Ferry A.L.M. Eskens, Joachim Drevs, Herlinde Dumez, Jaap Verweij, C. Brindley and Sebastian Böttcher. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.